Financial Ratios Garofalo Health Care S.p.A.
Equities
GHC
IT0005345233
Healthcare Facilities & Services
Real-time
Other stock markets
|
5-day change | 1st Jan Change | ||
5.180 EUR | +0.58% |
|
-1.52% | -5.13% |
Jun. 12 | Futures Slide; Mib Drops Over 200 Points | AN |
Jun. 11 | Mib down slightly; Azimut takes the lead | AN |
Fiscal Period: December | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
---|---|---|---|---|---|---|---|---|---|---|
Profitability | ||||||||||
Return on Assets | 2.89 | 3.89 | 3.92 | 3.8 | 3.77 | |||||
Return on Total Capital | 4.02 | 5.49 | 5.54 | 5.57 | 5.43 | |||||
Return On Equity % | 5.96 | 8.12 | 7.94 | 7.2 | 6.89 | |||||
Return on Common Equity | 5.96 | 8.12 | 7.94 | 7.2 | 6.99 | |||||
Margin Analysis | ||||||||||
Gross Profit Margin % | 20.98 | 22.45 | 22.28 | 22.04 | 21.34 | |||||
SG&A Margin | 0.83 | 0.24 | 0.26 | 0.24 | 0.22 | |||||
EBITDA Margin % | 14.3 | 16.49 | 17.2 | 16.83 | 15.16 | |||||
EBITA Margin % | 10.01 | 12.12 | 12.54 | 12.04 | 10.67 | |||||
EBIT Margin % | 9.95 | 12.01 | 12.46 | 11.98 | 10.63 | |||||
Income From Continuing Operations Margin % | 5.7 | 6.69 | 6.7 | 5.7 | 4.67 | |||||
Net Income Margin % | 5.7 | 6.69 | 6.69 | 5.68 | 4.64 | |||||
Net Avail. For Common Margin % | 5.7 | 6.69 | 6.69 | 5.68 | 4.64 | |||||
Normalized Net Income Margin | 6.04 | 6.56 | 6.94 | 5.71 | 4.82 | |||||
Levered Free Cash Flow Margin | 6.62 | 5.42 | 8.31 | 12.58 | 1.92 | |||||
Unlevered Free Cash Flow Margin | 7.39 | 6.36 | 9.13 | 14.33 | 3.79 | |||||
Asset Turnover | ||||||||||
Asset Turnover | 0.46 | 0.52 | 0.5 | 0.51 | 0.57 | |||||
Fixed Assets Turnover | 1.32 | 1.5 | 1.46 | 1.54 | 1.71 | |||||
Receivables Turnover (Average Receivables) | 3.57 | 4.08 | 4.16 | 4.07 | 4.32 | |||||
Inventory Turnover (Average Inventory) | 50.85 | 55.95 | 58.08 | 58.1 | 63.13 | |||||
Short Term Liquidity | ||||||||||
Current Ratio | 1.02 | 1 | 0.92 | 0.71 | 1.14 | |||||
Quick Ratio | 0.94 | 0.93 | 0.86 | 0.66 | 1.02 | |||||
Operating Cash Flow to Current Liabilities | 0.24 | 0.28 | 0.33 | 0.24 | 0.24 | |||||
Days Sales Outstanding (Average Receivables) | 102.49 | 89.41 | 87.66 | 89.73 | 84.67 | |||||
Days Outstanding Inventory (Average Inventory) | 7.2 | 6.52 | 6.28 | 6.28 | 5.8 | |||||
Average Days Payable Outstanding | 77.26 | 68.33 | 71.44 | 88.42 | 86.56 | |||||
Cash Conversion Cycle (Average Days) | 32.42 | 27.61 | 22.51 | 7.58 | 3.91 | |||||
Long Term Solvency | ||||||||||
Total Debt/Equity | 60.24 | 70.41 | 63.18 | 75.78 | 76.86 | |||||
Total Debt / Total Capital | 37.59 | 41.32 | 38.72 | 43.11 | 43.46 | |||||
LT Debt/Equity | 44.21 | 52.98 | 47.32 | 54.47 | 67.04 | |||||
Long-Term Debt / Total Capital | 27.59 | 31.09 | 29 | 30.99 | 37.91 | |||||
Total Liabilities / Total Assets | 55.81 | 58.39 | 56.78 | 62.21 | 60.82 | |||||
EBIT / Interest Expense | 8.11 | 8.03 | 9.48 | 4.26 | 3.57 | |||||
EBITDA / Interest Expense | 12.56 | 11.63 | 13.69 | 6.26 | 5.3 | |||||
(EBITDA - Capex) / Interest Expense | 8.23 | 6.12 | 10.4 | 4.76 | 3.99 | |||||
Total Debt / EBITDA | 3.84 | 3.75 | 3.07 | 3.54 | 3.47 | |||||
Net Debt / EBITDA | 3.06 | 2.91 | 2.52 | 3.19 | 3.11 | |||||
Total Debt / (EBITDA - Capex) | 5.87 | 7.12 | 4.04 | 4.65 | 4.61 | |||||
Net Debt / (EBITDA - Capex) | 4.68 | 5.52 | 3.32 | 4.19 | 4.13 | |||||
Growth Over Prior Year | ||||||||||
Total Revenues, 1 Yr. Growth % | 6.39 | 35.21 | 13.12 | 14.4 | 27.76 | |||||
Gross Profit, 1 Yr. Growth % | -0.78 | 61.16 | 17.82 | 17.53 | 24.81 | |||||
EBITDA, 1 Yr. Growth % | -10.92 | 62.61 | 14.46 | 13.89 | 9.75 | |||||
EBITA, 1 Yr. Growth % | -11.25 | 96.25 | 20.67 | 20.25 | 12.78 | |||||
EBIT, 1 Yr. Growth % | -9.97 | 99.32 | 22.37 | 22.83 | 15.14 | |||||
Earnings From Cont. Operations, 1 Yr. Growth % | -10.41 | 59.9 | 13.75 | -2.61 | 4.67 | |||||
Net Income, 1 Yr. Growth % | -10.36 | 59.87 | 13.76 | -2.93 | 4.34 | |||||
Normalized Net Income, 1 Yr. Growth % | -12.97 | 103.97 | 25.56 | 6.51 | 10.02 | |||||
Diluted EPS Before Extra, 1 Yr. Growth % | -12.5 | 50 | 14.29 | -25 | 33.33 | |||||
Accounts Receivable, 1 Yr. Growth % | 12.9 | 21.67 | 2.35 | 32.05 | 11.73 | |||||
Inventory, 1 Yr. Growth % | 18.65 | 23.95 | -1.8 | 31.55 | 8.78 | |||||
Net Property, Plant and Equip., 1 Yr. Growth % | 2.54 | 36.34 | 2.22 | 14.05 | 16.13 | |||||
Total Assets, 1 Yr. Growth % | 6.53 | 36.24 | 3.08 | 23.29 | 6.78 | |||||
Tangible Book Value, 1 Yr. Growth % | -43.85 | -165.67 | 48.23 | 813.62 | -33.76 | |||||
Common Equity, 1 Yr. Growth % | 5.85 | 28.2 | 7.15 | 7.1 | 7.87 | |||||
Cash From Operations, 1 Yr. Growth % | 21.36 | 58.14 | 20.81 | 13.99 | -30.02 | |||||
Capital Expenditures, 1 Yr. Growth % | 24.79 | 110.99 | -40.36 | 11.59 | 18.48 | |||||
Levered Free Cash Flow, 1 Yr. Growth % | 46.15 | 33.64 | 83.37 | 91.93 | -53.46 | |||||
Unlevered Free Cash Flow, 1 Yr. Growth % | 43.39 | 37.59 | 70.51 | 97.15 | -31.32 | |||||
Compound Annual Growth Rate Over Two Years | ||||||||||
Total Revenues, 2 Yr. CAGR % | 15.71 | 20.39 | 23.94 | 13.76 | 20.9 | |||||
Gross Profit, 2 Yr. CAGR % | 8.26 | 20.26 | 34.78 | 15.48 | 20.59 | |||||
EBITDA, 2 Yr. CAGR % | 3.62 | 18.29 | 38.84 | 13.17 | 14.51 | |||||
EBITA, 2 Yr. CAGR % | -2.24 | 20.97 | 51.86 | 15.16 | 16.69 | |||||
EBIT, 2 Yr. CAGR % | -1.77 | 21.64 | 53.26 | 16.06 | 17.97 | |||||
Earnings From Cont. Operations, 2 Yr. CAGR % | -8.48 | 19.69 | 34.86 | 5.25 | 0.96 | |||||
Net Income, 2 Yr. CAGR % | -6.87 | 19.71 | 34.86 | 5.09 | 0.64 | |||||
Normalized Net Income, 2 Yr. CAGR % | -0.24 | 13.46 | 56.61 | 8.7 | 7.11 | |||||
Diluted EPS Before Extra, 2 Yr. CAGR % | -8.07 | 14.56 | 30.93 | -7.42 | 0 | |||||
Accounts Receivable, 2 Yr. CAGR % | 32.01 | 17.2 | 11.6 | 16.26 | 21.47 | |||||
Inventory, 2 Yr. CAGR % | 25.38 | 21.27 | 10.32 | 13.66 | 19.62 | |||||
Net Property, Plant and Equip., 2 Yr. CAGR % | 30.72 | 18.24 | 18.05 | 7.97 | 15.08 | |||||
Total Assets, 2 Yr. CAGR % | 26.1 | 20.47 | 18.51 | 12.73 | 14.74 | |||||
Tangible Book Value, 2 Yr. CAGR % | -73.89 | -39.28 | -1.34 | 268 | 146 | |||||
Common Equity, 2 Yr. CAGR % | 6.58 | 16.49 | 17.2 | 7.12 | 7.48 | |||||
Cash From Operations, 2 Yr. CAGR % | 11.36 | 38.53 | 38.22 | 17.35 | -10.69 | |||||
Capital Expenditures, 2 Yr. CAGR % | 10.35 | 62.26 | 12.17 | -18.42 | 14.98 | |||||
Levered Free Cash Flow, 2 Yr. CAGR % | 9.2 | 27.71 | 52.48 | 78.23 | -38.74 | |||||
Unlevered Free Cash Flow, 2 Yr. CAGR % | 11.91 | 29.67 | 49.79 | 75.04 | -18.44 | |||||
Compound Annual Growth Rate Over Three Years | ||||||||||
Total Revenues, 3 Yr. CAGR % | 15.01 | 22.18 | 18.09 | 20.68 | 18.25 | |||||
Gross Profit, 3 Yr. CAGR % | 10.32 | 19.55 | 17.69 | 27.16 | 18.16 | |||||
EBITDA, 3 Yr. CAGR % | 6.46 | 19.03 | 18.37 | 29.21 | 13.82 | |||||
EBITA, 3 Yr. CAGR % | 2.68 | 16.37 | 19.81 | 36.34 | 14.51 | |||||
EBIT, 3 Yr. CAGR % | 3.08 | 16.61 | 20.36 | 37.25 | 15.13 | |||||
Earnings From Cont. Operations, 3 Yr. CAGR % | -1.44 | 10.23 | 17.68 | 20.99 | 5.05 | |||||
Net Income, 3 Yr. CAGR % | -1.27 | 11.51 | 17.7 | 20.86 | 4.84 | |||||
Normalized Net Income, 3 Yr. CAGR % | 2.1 | 13.75 | 15.68 | 32.15 | 8.37 | |||||
Diluted EPS Before Extra, 3 Yr. CAGR % | -11.21 | 8.23 | 14.47 | 8.74 | 4.55 | |||||
Accounts Receivable, 3 Yr. CAGR % | 16.94 | 28.47 | 12.03 | 18.04 | 14.73 | |||||
Inventory, 3 Yr. CAGR % | 14.03 | 24.9 | 13.03 | 16.99 | 12.01 | |||||
Net Property, Plant and Equip., 3 Yr. CAGR % | 20.95 | 32.57 | 12.64 | 16.7 | 10.63 | |||||
Total Assets, 3 Yr. CAGR % | 28.59 | 29.4 | 14.37 | 20.08 | 10.71 | |||||
Tangible Book Value, 3 Yr. CAGR % | -41.17 | -64.49 | -18.24 | 107.18 | 107.78 | |||||
Common Equity, 3 Yr. CAGR % | 28.72 | 13.35 | 13.29 | 13.73 | 7.37 | |||||
Cash From Operations, 3 Yr. CAGR % | -5.03 | 25.17 | 32.35 | 29.62 | -1.23 | |||||
Capital Expenditures, 3 Yr. CAGR % | 63.19 | 36.96 | 16.23 | 11.98 | -7.62 | |||||
Levered Free Cash Flow, 3 Yr. CAGR % | -8.43 | 10 | 41.58 | 59.11 | -14.68 | |||||
Unlevered Free Cash Flow, 3 Yr. CAGR % | -5.98 | 13.66 | 39.96 | 59.16 | 1.11 | |||||
Compound Annual Growth Rate Over Five Years | ||||||||||
Total Revenues, 5 Yr. CAGR % | 10.41 | 17.85 | 18.68 | 18.85 | 19.2 | |||||
Gross Profit, 5 Yr. CAGR % | 9.63 | 19.6 | 17.14 | 16.86 | 17.95 | |||||
EBITDA, 5 Yr. CAGR % | 9.95 | 23.14 | 17.57 | 17.47 | 16.4 | |||||
EBITA, 5 Yr. CAGR % | 9.41 | 24.77 | 15.97 | 15.27 | 16.44 | |||||
EBIT, 5 Yr. CAGR % | 9.32 | 24.6 | 16.23 | 15.52 | 16.81 | |||||
Earnings From Cont. Operations, 5 Yr. CAGR % | 11.85 | 27.32 | 11.73 | 8.21 | 10.68 | |||||
Net Income, 5 Yr. CAGR % | 12.25 | 27.96 | 11.85 | 8.9 | 10.55 | |||||
Normalized Net Income, 5 Yr. CAGR % | 10.49 | 23.65 | 13.61 | 10.74 | 9.43 | |||||
Diluted EPS Before Extra, 5 Yr. CAGR % | 4.91 | 18.07 | 3.71 | 1.68 | 8.45 | |||||
Accounts Receivable, 5 Yr. CAGR % | 10.38 | 15.65 | 14.77 | 23.44 | 15.71 | |||||
Inventory, 5 Yr. CAGR % | 3.78 | 9.64 | 12.53 | 20.28 | 15.62 | |||||
Net Property, Plant and Equip., 5 Yr. CAGR % | 14.25 | 21.69 | 19.78 | 22.12 | 13.61 | |||||
Total Assets, 5 Yr. CAGR % | 22.17 | 29.68 | 24.46 | 22.45 | 14.52 | |||||
Tangible Book Value, 5 Yr. CAGR % | -30.19 | -36.44 | -27.65 | -9.52 | 27.03 | |||||
Common Equity, 5 Yr. CAGR % | 22.42 | 27.68 | 23.98 | 10.82 | 10.93 | |||||
Cash From Operations, 5 Yr. CAGR % | 8.28 | 24.07 | 10.35 | 21.98 | 13.09 | |||||
Capital Expenditures, 5 Yr. CAGR % | 20.64 | 37.71 | 40.47 | 11.32 | 15.73 | |||||
Levered Free Cash Flow, 5 Yr. CAGR % | - | 16.16 | 8.32 | 32.03 | -0.79 | |||||
Unlevered Free Cash Flow, 5 Yr. CAGR % | - | 18.31 | 9.71 | 33.89 | 10.7 |
- Stock Market
- Equities
- GHC Stock
- Financials Garofalo Health Care S.p.A.
- Financial Ratios
Select your edition
All financial news and data tailored to specific country editions